Today: 7 February 2026
Subscribe
Browse Category

Pharmaceuticals News 30 December 2025 - 31 December 2025

Pfizer stock flat before the bell as report flags 2026 U.S. drug price hikes, including 15% Comirnaty rise

Pfizer stock flat before the bell as report flags 2026 U.S. drug price hikes, including 15% Comirnaty rise

NEW YORK, December 31, 2025, 08:51 ET — Premarket Pfizer Inc shares were little changed in premarket trading on Wednesday after a report showed the drugmaker is leading a new round of U.S. list-price increases for 2026. The stock was down about 0.02% at $24.99, after closing Tuesday at roughly $25.00. The issue matters now because drug pricing has returned to the front burner in Washington, with the Trump administration pressing manufacturers to rein in costs. Year-end is also when many companies set list-price changes that typically take effect in early January. For investors, higher list prices can support revenue
31 December 2025
·····
Hims & Hers stock dips in premarket as GLP-1 drug pricing pressure stays in focus

Hims & Hers stock dips in premarket as GLP-1 drug pricing pressure stays in focus

NEW YORK, December 31, 2025, 05:39 ET — Premarket Shares of Hims & Hers Health Inc (HIMS) fell 0.5% to $32.87 in premarket trading on Wednesday after closing down 3.1% at $33.04 in the prior session. The stock has traded between $23.97 and $72.98 over the past 52 weeks. Google The drift lower keeps attention on the telehealth group’s exposure to the fast-moving market for GLP-1 weight-loss drugs — a category that has become a major battleground for pricing, access and consumer demand. That matters now because GLP-1 drugs, a class of diabetes and obesity medicines that reduce appetite, are
31 December 2025
·······
Vanda Pharma stock jumps premarket after FDA approves Nereus, first new motion-sickness vomiting drug in decades

Vanda Pharma stock jumps premarket after FDA approves Nereus, first new motion-sickness vomiting drug in decades

NEW YORK, December 31, 2025, 04:27 ET — Premarket Vanda Pharmaceuticals’ shares surged about 18% in premarket trading on Wednesday after the U.S. Food and Drug Administration approved its motion-sickness vomiting drug, Nereus (tradipitant). StockAnalysis+1 The approval matters now because Vanda is moving from a long-running regulatory story to a commercial one, with investors shifting quickly to questions of launch execution, insurance coverage and pricing. The company said it expects to launch Nereus in the coming months. Reuters+1 It also gives Vanda a fresh catalyst heading into year-end trading, when extended-hours moves can be amplified by thinner liquidity. Shares closed
31 December 2025
····
Pfizer stock flat after hours as TD Cowen sticks with Hold; Feb. 3 results ahead

Pfizer stock flat after hours as TD Cowen sticks with Hold; Feb. 3 results ahead

NEW YORK, December 30, 2025, 19:40 ET — After-hours Pfizer Inc. shares were little changed in late after-hours trading on Tuesday, down about 0.02% at $24.99, after moving between $24.92 and $25.10 in the regular session. After-hours trading is the session after the 4 p.m. ET close, when volumes can be thinner and moves can be sharper. The quiet tape does not mean investors have gone quiet on Pfizer. Traders have been treating the stock as a test case for whether Big Pharma can defend cash flows as pandemic-era sales fade and older blockbusters face cheaper rivals. That backdrop has
31 December 2025
·····
JNJ stock slips after hours as Johnson & Johnson closes $3.05B Halda Therapeutics deal

JNJ stock slips after hours as Johnson & Johnson closes $3.05B Halda Therapeutics deal

NEW YORK, December 30, 2025, 18:51 ET — After-hours Johnson & Johnson (JNJ) shares edged lower in after-hours trading on Tuesday after the healthcare conglomerate said it had completed its acquisition of Halda Therapeutics. The stock was down 0.3% at $206.91. The completion matters because investors are resetting portfolios into year-end with interest rates back in focus and dealmaking under a brighter spotlight. For J&J, the question is whether a new oncology platform can expand its pipeline without pressuring near-term profit metrics. The timing also pushes the spotlight onto management’s next set of targets. With the company set to talk
31 December 2025
····
Eli Lilly stock ticks up after hours as China price cuts put Mounjaro, Wegovy in focus

Eli Lilly stock ticks up after hours as China price cuts put Mounjaro, Wegovy in focus

NEW YORK, December 30, 2025, 5:08 PM ET — After-hours Eli Lilly shares were up 0.1% in after-hours trading on Tuesday at $1,079.75 after a Reuters report said it and Novo Nordisk are lowering prices of their top-selling obesity drugs in China. Reuters The pricing move matters because investors have treated Lilly’s obesity franchise as a main growth engine, helping support a premium valuation. A sharper-than-expected push to discount in large markets can pressure margins, even if it expands the customer base. It also lands as drugmakers pivot toward cash-pay channels — patients paying out of pocket, rather than relying
30 December 2025
····
Terns Pharmaceuticals stock slides today, testing the $40 level after December share sale

Terns Pharmaceuticals stock slides today, testing the $40 level after December share sale

NEW YORK, December 30, 2025, 15:30 ET — Regular session. Shares of Terns Pharmaceuticals, Inc. fell 2.8% to $40.34 in afternoon trading on Tuesday, after swinging between $39.99 and $41.98. The pullback puts the stock back around $40, the price used in the company’s recent upsized equity offering — a level traders often watch after a big deal resets supply and demand. That matters now because Terns’ December financing and trial update put new attention on how quickly the biotech can turn early leukemia data into larger studies, while also giving it a much longer cash runway. Biotech shares were
30 December 2025
·····
Catalyst Pharmaceuticals stock drops 3% today as CPRX lags biotech in thin year-end trade

Catalyst Pharmaceuticals stock drops 3% today as CPRX lags biotech in thin year-end trade

NEW YORK, December 30, 2025, 2:30 PM ET — Regular session Shares of Catalyst Pharmaceuticals, Inc. fell 3.0% to $23.33 in afternoon trading on Tuesday. The stock has traded between $23.30 and $24.10 so far in the session. The drop matters because trading can get choppy in the final days of the year, when fewer investors are active and price moves can be exaggerated. Mid-cap healthcare names often swing more than the major indexes in that setting. Catalyst fell 1.2% on Monday to close at $24.06, according to MarketWatch data, and it remains well below its June 9 52-week high
30 December 2025
·····
Why Cogent Biosciences stock is down today after its FDA filing for bezuclastinib

Why Cogent Biosciences stock is down today after its FDA filing for bezuclastinib

NEW YORK, December 30, 2025, 14:40 ET — Regular session Shares of Cogent Biosciences, Inc. fell 2.7% to $36.88 on Tuesday after the biotech said it submitted a New Drug Application to the U.S. Food and Drug Administration for its drug candidate bezuclastinib in nonadvanced systemic mastocytosis. Yahoo Finance An NDA is the formal request asking the FDA to review a drug for marketing approval, a key inflection point for development-stage biotechs with no products on the market. U.S. Food and Drug Administration Systemic mastocytosis is a rare disorder marked by abnormal accumulation and activation of mast cells — immune
30 December 2025
·····
Amgen stock dips as Lumakras combo trial ends; MariTide data now the next watch

Amgen stock dips as Lumakras combo trial ends; MariTide data now the next watch

NEW YORK, December 30, 2025, 2:56 PM ET — Regular session Amgen Inc. shares were down 0.4% at $328.32 at 2:56 p.m. ET on Tuesday, after trading between $325.90 and $330.18. The modest move matters because investors are grading Amgen’s pipeline for new growth while several mature products face price pressure and biosimilar competition. Oncology and obesity remain two key swing factors for the stock heading into 2026. Biotech stocks lagged, with the iShares Nasdaq Biotechnology ETF down about 1.1%, while the healthcare sector ETF was roughly flat and the S&P 500 ETF hovered near unchanged. Verastem Oncology said it
30 December 2025
·····
Arrowhead Pharmaceuticals stock slides today as biotech dips; ARWR investors eye January obesity data

Arrowhead Pharmaceuticals stock slides today as biotech dips; ARWR investors eye January obesity data

NEW YORK, December 30, 2025, 13:47 ET — Regular session Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) shares were down 3.6% at $67.09 at 1:47 p.m. ET on Tuesday, after trading between $65.94 and $69.95. The stock’s drop came as biotech weakened but the wider market held steady, a setup that can amplify moves in higher-volatility drug developers. The SPDR S&P Biotech ETF (XBI) fell 1.3% and the iShares Nasdaq Biotechnology ETF (IBB) dropped 1.1%, while the S&P 500 tracker SPY was flat and the Nasdaq-100 proxy QQQ edged higher. The timing matters because Arrowhead is heading into an early-January news window where
30 December 2025
····
Rhythm Pharmaceuticals (RYTM) stock falls today as biotech weakens; FDA decision stays in focus

Rhythm Pharmaceuticals (RYTM) stock falls today as biotech weakens; FDA decision stays in focus

NEW YORK, December 30, 2025, 13:33 ET — Regular session Rhythm Pharmaceuticals shares were down 4.2% at $107.85 at 1:33 p.m. ET on Tuesday, after trading as low as $106.65. The move matters because Rhythm is a single-product rare-disease biotech whose stock has tended to swing on regulatory and clinical milestones for Imcivree, its obesity drug. Investors are watching the company’s next U.S. Food and Drug Administration decision closely. With the next major catalyst still ahead, the stock can move sharply on broader risk sentiment in biotech, even when there is no fresh company news. The SPDR S&P Biotech ETF
30 December 2025
····
1 … 27 28 29 30 31 … 56

Stock Market Today

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

7 February 2026
Seagate shares rose 5.9% to $429.32 Friday after Citigroup raised its price target to $480 and reiterated a buy rating. The gain ended a two-day slide but left the stock 6.6% below its Feb. 3 high. CEO Dave Mosley sold 20,000 shares on Feb. 2 under a pre-arranged plan, SEC filings show. U.S. jobs and inflation data next week are seen as key tests for tech stocks.
Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

7 February 2026
Cummins shares jumped 6.8% to $577.73 Friday, recovering from a nearly 9% post-earnings drop the day before. The company reported Q4 revenue up 1% to $8.54 billion, took a $218 million charge tied to its hydrogen business, and guided for 2026 EBITDA of 17–18% of sales. Demand for data center generators offset weakness in North American truck markets. Analyst reaction was mixed; Truist raised its price target.
Corning stock hits first record close since 2000 as jobs, CPI data loom

Corning stock hits first record close since 2000 as jobs, CPI data loom

7 February 2026
Corning shares surged 8.3% to $122.16 Friday, their highest close since the dot-com era, after Meta agreed to buy up to $6 billion in fiber-optic cables. The stock is up 40% since late 2025, fueled by strong first-quarter guidance and AI data-center demand. Insiders sold shares following the rally, SEC filings show. Investors await next week’s U.S. jobs and inflation data for rate signals.
Go toTop